- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00055809
Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Phase II Study Of Bevacizumab And PEG Interferon Alpha-2b (PEG Intron) In Patients With Metastatic, Or Unresectable Carcinoid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
I. Determine the progression-free survival rate in patients with metastatic or unresectable carcinoid tumors treated with bevacizumab and PEG-interferon alfa-2b.
II. Determine the tumor response rate (complete and partial) in patients treated with this regimen.
III. Determine the biochemical response rate of patients treated with this regimen.
IV. Determine the qualitative and quantitative toxicity and reversibility of toxicity of this regimen in these patients.
OUTLINE: This is a randomized study. Patients are treated in 2 stages.
Stage I: Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive bevacizumab IV on day 1.
Arm II: Patients receive PEG-interferon alfa-2b subcutaneously (SC) on days 1, 8, and 15.
In both arms, courses repeat every 3 weeks. Patients with progressive disease at 9 weeks proceed to stage II. All other patients proceed to stage II after 18 weeks on stage I.
Stage II: Patients receive bevacizumab IV on day 1 and PEG-interferon alfa-2b SC once weekly. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) and remain in CR for 2 additional courses come off study. Patients are followed for survival.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed carcinoid tumor
- Metastatic or unresectable local-regional disease
- Measurable disease
- No osseous metastasis as the only site of disease
- No history or clinical evidence of CNS disease (e.g., primary brain tumor or any brain metastasis)
- Performance status - Zubrod 0-2
- Performance status - Karnofsky 70-100%
- At least 12 weeks
- See Immunologic
- Absolute granulocyte count > 1,500/mm^3
- Platelet count > 100,000/mm^3
- Hemoglobin > 8 g/dL
- No bleeding diathesis or coagulopathy
- No hemoglobinopathies (e.g., thalassemia) or any other cause of hemolytic anemia
- Bilirubin < 1.5 mg/dL
- INR < 1.5 (if receiving warfarin)
- No evidence of decompensated liver disease (e.g., ascites, bleeding varices, or spontaneous encephalopathy)
- Creatinine < 1.5 mg/dL
No baseline proteinuria
- Patients with proteinuria (≥ 2+ or ≥ 100 mg/dL on urinalysis) are allowed provided 24-hour urinary protein is < 500 mg
- No New York Heart Association grade II-IV congestive heart failure
- No serious cardiac arrhythmia requiring medication
- No clinically significant peripheral vascular disease
- No history of stroke
None of the following within the past 6 months:
- Uncontrolled hypertension
- Transient ischemic attack
- Cerebrovascular accident
- Unstable angina
- Myocardial infarction
- No chronic pulmonary disease (e.g., chronic obstructive pulmonary disease)
- No documented pulmonary hypertension
None of the following immunologically mediated diseases:
- Inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis)
- Rheumatoid arthritis
- Idiopathic thrombocytopenia purpura
- Systemic lupus erythematosus
- Autoimmune hemolytic anemia
- Scleroderma
- Severe psoriasis
- No serious concurrent infections
- No active infection requiring parental antibiotics on day 0
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No known hypersensitivity to interferon alfa or to any excipient or vehicle included in its formulation or delivery system
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No significant traumatic injury within the past 4 weeks
- No preexisting thyroid abnormality for which thyroid function can not be normalized by medication
- No concurrent nonmalignant uncontrolled medical illness or one whose control may be jeopardized by the complications of this study therapy
- No uncontrolled psychiatric disorder
- No psychiatric disorders that would preclude study compliance
- No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No serious nonhealing wound ulcer or bone fracture
- No seizures not controlled with standard medical therapy
Prior immunotherapy allowed
- No prior interferon
- No concurrent immunotherapy
- At least 4 weeks since prior chemotherapy, including radiosensitizers
- No more than 1 prior chemotherapy regimen, including radiosensitizers
- No concurrent chemotherapy
At least 4 weeks since prior radiotherapy
- Prior radiotherapy must not have contained the single evaluable lesion of this study in a radiation field
- No concurrent radiotherapy
- At least 4 weeks since prior major surgery or open biopsy (1 week for minor surgery) and recovered
- No concurrent or recent full-dose anticoagulants or thrombolytic agents (except as required to maintain patency of preexisting, permanent indwelling IV catheters)
- No concurrent chronic daily aspirin (more than 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (bevacizumab)
Patients receive bevacizumab IV on day 1.
|
Given IV
Other Names:
Optional correlative studies
|
Experimental: Arm II (PEG-interferon alfa-2b)
Patients receive PEG-interferon alfa-2b SC on days 1, 8, and 15.
|
Optional correlative studies
Given SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Tumor response rate (CR + PR) as measured by RECIST criteria
Time Frame: Up to 4 years
|
Up to 4 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression free survival
Time Frame: From the time of initial treatment to the time of PD or death, assessed up to 4 years
|
From the time of initial treatment to the time of PD or death, assessed up to 4 years
|
Biochemical response rate measured after treatment
Time Frame: Up to 4 years
|
Up to 4 years
|
Toxicity graded according to CTC v3.0 criteria for adverse outcomes
Time Frame: Up to 4 years
|
Up to 4 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Neoplasms
- Gastrointestinal Neoplasms
- Carcinoid Tumor
- Malignant Carcinoid Syndrome
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Interferons
- Interferon-alpha
- Antibodies
- Interferon alpha-2
- Immunoglobulins
- Bevacizumab
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Peginterferon alfa-2b
Other Study ID Numbers
- NCI-2012-02519
- N01CM62202 (U.S. NIH Grant/Contract)
- MDA-ID-02063
- CDR0000271225 (Registry Identifier: PDQ (Physician Data Query))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Gastrointestinal Carcinoid Tumor
-
National Cancer Institute (NCI)CompletedMetastatic Gastrointestinal Carcinoid Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Pulmonary Carcinoid TumorCanada
-
National Cancer Institute (NCI)TerminatedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Regional Gastrointestinal Carcinoid Tumor | Pulmonary Carcinoid TumorUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Pulmonary Carcinoid TumorUnited States
-
National Cancer Institute (NCI)CompletedNeuroendocrine Tumor | Gastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA SyndromeUnited States
-
Yale UniversityNational Cancer Institute (NCI)TerminatedDoxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine TumorsMetastatic Cancer | Islet Cell Tumor | Gastrointestinal Carcinoid TumorUnited States
-
National Cancer Institute (NCI)CompletedGastrinoma | Glucagonoma | Insulinoma | Metastatic Gastrointestinal Carcinoid Tumor | Pancreatic Polypeptide Tumor | Recurrent Gastrointestinal Carcinoid Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | WDHA SyndromeUnited States
-
Roswell Park Cancer InstituteNeuroEndocrine Tumor Research Foundation (NETRF)RecruitingLung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid TumorUnited States
-
Mid-Atlantic Oncology ProgramCancer Biotherapy Research GroupCompletedLung Cancer | Gastrointestinal Carcinoid TumorUnited States
-
National Cancer Institute (NCI)UnknownLung Cancer | Metastatic Cancer | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic SyndromeSpain, United Kingdom, Germany, Netherlands, Israel, Sweden, Poland, Denmark, Greece, Italy
-
Shanghai EpimAb Biotherapeutics Co., Ltd.Labcorp Corporation of America Holdings, IncRecruitingNeoplasms | Neoplasm Metastasis | Metastatic Gastrointestinal Carcinoid TumorUnited States, China
Clinical Trials on bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States